Intellia Therapeutics, Inc.

Disease Roundup: Genomic Medicine Candidates for...

Jul. 20, 2022

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

Gene-Edited T Cells Treat Leukaemia and Solid...

May. 23, 2022

Researchers from Italy’s Ospedale San Raffaele Scientific Institute, in collaboration with Intellia Therapeutics, have used CRISPR to introduce...

Clinical update: FDA Upgrades Status for Two...

Mar. 16, 2022

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

First Patient Dosed in CRISPR Trial for Acute...

Mar. 9, 2022

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...

Clinical Update: CRISPR Therapy for Transthyretin...

Mar. 2, 2022

In this week's update, we provide news about Intellia Therapeutics' and Regeneron's ongoing Phase 1 trial for NTLA-2001 in transthyretin amyloidosis....

CRISPR Clinical Trial Roundup: Rare Diseases

Feb. 16, 2022

In this week's clinical trial update, we summarise the ongoing in vivo CRISPR clinical trials for three distinct rare genetic diseases: hereditary...

CRISPR Medicine in 2021 – What a Phenomenal Year...

Dec. 28, 2021

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

News: CMN Weekly (17 December 2021) - Your Weekly...

Dec. 17, 2021

Some of the best links we picked up around the internet